Puma Biotechnology | PBYI - Pre Tax Profit


Puma Biotechnology reported $20.61M in Pre-Tax Profit for its fiscal quarter ending in September of 2024.





Pre Tax Profit Change Date
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
Amgen USD 2.08B 570M Mar/2026
Biogen USD 647.3M 269.6M Jun/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Daiichi Sankyo JPY -6.52B 113.25B Mar/2026
Exelixis USD 262.68M 5.01M Jun/2026
Gilead Sciences USD -7.53B 10.11B Jun/2026
Glaxosmithkline GBP 2.14B 312M Mar/2026
Incyte USD 751.51M 407.91M Jun/2026
MacroGenics USD -36.77M 21.84M Mar/2026
Moderna USD -1.33B 535M Mar/2026
Novartis USD 4.27B 430M Jun/2026
Pfizer USD -653M 5.84B Jun/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.53B 696.6M Jun/2026
Roche Holding CHF 11.17B 6.38B Jun/2026
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sarepta Therapeutics USD -1.75M 344.92M Jun/2026
Takeda JPY 162.72B 215.2B Jun/2026
TG Therapeutics USD 10.23M 10.13M Jun/2026
Ultragenyx Pharmaceutical USD -91M 93M Jun/2026
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024
Vertex Pharmaceuticals USD 1.39B 138.9M Jun/2026